Most Likely Diagnosis: Peripheral Arterial Disease (Vascular Claudication)
This presentation is classic for vascular claudication from peripheral arterial disease, NOT statin-associated myopathy. The key distinguishing feature is that his symptoms are triggered by motion and relieved after 10 minutes of rest—this is the hallmark of intermittent claudication, not statin myopathy.
Critical Diagnostic Distinctions
Why This is NOT Statin Myopathy
While this patient is on a statin, several features argue strongly against statin-associated muscle symptoms (SAMS):
- Statin myalgia is typically present at rest and does not follow the classic exercise-relief pattern described here 1
- Statin myopathy characteristics include bilateral proximal muscle pain that is constant or worsens with activity but does NOT improve predictably after 10 minutes of rest 1
- The patient has been highly active (biking 20 miles 3x/week, daily walking, weights 2x/week) without prior symptoms—statin myopathy is actually more likely in patients with high levels of physical activity 1, yet he tolerated this regimen until now
- Timing is wrong: Statin myalgia typically occurs within weeks to months of initiation 1, not after prolonged tolerance
Why This IS Vascular Claudication
The clinical presentation is textbook for arterial insufficiency:
- Symmetric bilateral thigh pain triggered by exertion
- Predictable relief after 10 minutes of rest (classic claudication pattern)
- Proximal location (thighs) suggests aortoiliac disease (Leriche syndrome)
- New onset in a 66-year-old male despite "no cardiovascular risk factors" (though he's on a statin, suggesting some indication existed)
Immediate Evaluation Required
Obtain ankle-brachial index (ABI) immediately as the first-line diagnostic test:
- ABI <0.90 confirms peripheral arterial disease
- If ABI is borderline (0.91-1.00) with high clinical suspicion, proceed to exercise ABI testing
- Consider CT angiography or MR angiography for anatomic assessment if intervention is being considered
Check creatine kinase (CK) level to definitively exclude statin myopathy 1, 2:
- Normal CK essentially rules out significant statin-induced muscle injury
- CK >4x upper limit of normal would warrant statin cessation
- CK >10x upper limit with renal injury indicates rhabdomyolysis requiring immediate intervention 1
Management Algorithm
If ABI Confirms PAD (Most Likely):
- Do NOT stop the statin—continue for critical cardiovascular protection
- Initiate antiplatelet therapy (aspirin or clopidogrel)
- Start cilostazol 100 mg twice daily for claudication symptoms (if no heart failure)
- Aggressive risk factor modification: smoking cessation if applicable, blood pressure control, diabetes management
- Supervised exercise therapy: structured walking program is first-line treatment
- Vascular surgery referral if symptoms are lifestyle-limiting despite medical therapy
If CK is Elevated (Less Likely):
Only if CK is significantly elevated (>4x ULN) with normal ABI:
- Temporarily discontinue statin until symptoms resolve 1
- Rechallenge with lower dose or alternative statin after symptom resolution 1, 2
- Consider intermittent dosing (e.g., rosuvastatin or atorvastatin 2-3 times weekly) 2
- Most patients (92%) successfully tolerate rechallenge with same or different statin 2
Critical Pitfalls to Avoid
Do not reflexively blame the statin for every muscle complaint in a patient taking statins—this leads to inappropriate discontinuation of life-saving therapy. The 2018 AHA/ACC guidelines emphasize that musculoskeletal symptoms are common in the general adult population at baseline 1.
Do not miss peripheral arterial disease by focusing solely on the statin. The exercise-relief pattern is pathognomonic for vascular claudication and requires urgent vascular evaluation and aggressive cardiovascular risk reduction.
Do not test for anti-HMGCR antibodies unless there is objective weakness, markedly elevated CK, and symptoms persist after statin discontinuation 1. Statin-associated autoimmune myopathy is exceedingly rare and characterized by progressive weakness, not exercise-induced pain with relief.
The patient's high activity level and lack of cardiovascular risk factors (per history) make this presentation particularly concerning for previously undiagnosed PAD that has now progressed to symptomatic disease. Vascular evaluation takes priority over statin modification.